Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(21):1586-1587; doi:10.1093/jnci/93.21.1586
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lynch, H. T.
Right arrow Articles by Rubinstein, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lynch, H. T.
Right arrow Articles by Rubinstein, W. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 21, 1586-1587, November 7, 2001
© 2001 Oxford University Press

EDITORIAL

Prophylactic Mastectomy: Obstacles and Benefits

Henry T. Lynch1, Jane F. Lynch1, Wendy S. Rubinstein1

Affiliations of authors: H. T. Lynch, J. F. Lynch, Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE; W. S. Rubinstein, Northwestern University Medical School and Evanston Northwestern Healthcare Center for Medical Genetics, Evanston, IL.

Correspondence to: Henry T. Lynch, M.D., Department of Preventive Medicine and Public Health, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178 (e-mail: htlynch@creighton.edu).

News in medicine, such as the potential lifesaving effects of bilateral prophylactic mastectomy as reported in this issue of the Journal by Hartmann et al. (1) and its implementation in clinical practice, does not, unfortunately, always travel fast! Bilateral prophylactic mastectomy for women at increased risk for breast cancer has been highly controversial, in part because of strong concerns such as, "Will it work? Will patients accept it? Will physicians recommend it?" Physicians often are reluctant to advocate new and particularly radical medical changes, such as bilateral prophylactic mastectomy, even though their patients may be at inordinately high risk for the hereditary breast–ovarian cancer syndrome because they carry a deleterious cancer-causing BRCA1 or BRCA2 gene mutation.

In their initial study, Hartmann et al. (2) used "high-risk" . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Science Technology Human ValuesHome page
I. Lowy and J. P. Gaudilliere
Localizing the Global: Testing for Hereditary Risks of Breast Cancer
Science Technology Human Values, May 1, 2008; 33(3): 299 - 325.
[Abstract] [PDF]

Home page
 J. Med. Genet.Home page
P Watson, S A Narod, R Fodde, A Wagner, J F Lynch, S T Tinley, C L Snyder, S A Coronel, B Riley, Y Kinarsky, et al.
Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer
J. Med. Genet., August 1, 2003; 40(8): 591 - 596.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. T. Lynch, C. L. Snyder, J. F. Lynch, B. D. Riley, and W. S. Rubinstein
Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist
J. Clin. Oncol., February 15, 2003; 21(4): 740 - 753.
[Abstract] [Full Text] [PDF]